{'fraction_non_alphanumeric': 0.04777870913663034, 'fraction_numerical': 0.03604358759430008, 'mean_word_length': 6.107142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Inhibitory effect of thrombin on the expression of secretory group IIA phospholipase A2

It is well known that the expression level of secretory group IIA phospholipase A2 (sPLA2‐IIA) is elevated in inflammatory diseases and lipopolysaccharide (LPS) up‐regulates the expression of sPLA2‐IIA in human umbilical vein endothelial cells (HUVECs). Recently, lower concentration thrombin could elicit anti‐inflammatory responses in HUVECs. Here, the effects of lower concentration thrombin on the expression of sPLA2‐IIA in LPS‐stimulated HUVECs were investigated. Prior treatment of cells with thrombin (25–75 pM) inhibited LPS‐induced sPLA2‐IIA expression by activating its receptor, protease‐activated receptor‐1 (PAR‐1). And pretreatment of cells with either PI3‐kinase inhibitor (LY294002) or cholesterol depleting agent (methyl‐β‐cyclodextrin, MβCD) abolished the inhibitory activity of thrombin against sPLA2‐IIA expression. Therefore, these results suggest that PAR‐1 activation by lower concentration thrombin inhibited LPS mediated expression of sPLA2‐IIA by PAR‐1 and PI3‐kinase‐dependent manner in lipid raft on the HUVECs. J. Cell. Biochem. 112: 2502–2507, 2011. © 2011 Wiley‐Liss, Inc.